Mahé Cédric, Gaffikin Lynne
Screening Group, International Agency for Research on Cancer (IARC/WHO), 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France.
Cancer Causes Control. 2005 Aug;16(6):657-66. doi: 10.1007/s10552-005-0296-4.
While the basic concepts associated with screening are simple, studying the value of new tests requires a very strict methodology. This paper summarizes lessons learned regarding appropriate methodologies to assess the value of new screening approaches using visual inspection with acetic acid (VIA), a screening test for cervical pre-cancerous lesions, as an example. In addition to being convenient to, safe for and acceptable by target community members, a screening test should be reliable and have good test characteristics (i.e. be able to discriminate well between early disease and non disease). Test reliability assesses the degree to which repeated measurements of the test yields the same result. To ensure reproducibility of study findings, test reliability should be assessed before any evaluation of test accuracy. The accuracy of a test (specificity and sensitivity) is measured using cross-sectional studies with adequate sample size. Several basic features are necessary to ensure internal validity for such studies: (a) final disease status data should be obtained for all subjects, (b) all tests results must be determined independently of previous results, (c) the reference standard used to determine the disease status should be accurate, (d) the full "spectrum" of the disease should be included in the study. The study results should also have external validity to be applicable to other populations to which the test will be applied. All these consideration are exemplified by 17 very heterogeneous studies published to date assessing VIA test accuracy. The assessment of a new screening test is the first step in researching a new cancer prevention strategy. For this reason, this step should be carefully addressed through rigorous studies.
虽然与筛查相关的基本概念很简单,但研究新测试的价值需要非常严格的方法。本文以使用醋酸目视检查(VIA)作为子宫颈癌前病变筛查测试为例,总结了在评估新筛查方法价值时有关适当方法的经验教训。除了要方便目标社区成员使用、对其安全且为他们所接受外,筛查测试还应可靠并具有良好的测试特性(即能够很好地区分早期疾病和非疾病)。测试可靠性评估测试的重复测量产生相同结果的程度。为确保研究结果的可重复性,应在评估测试准确性之前评估测试可靠性。测试的准确性(特异性和敏感性)使用具有足够样本量的横断面研究来衡量。为确保此类研究的内部有效性,需要几个基本特征:(a)应获取所有受试者的最终疾病状态数据;(b)所有测试结果必须独立于先前结果来确定;(c)用于确定疾病状态的参考标准应准确;(d)研究应涵盖疾病的整个“范围”。研究结果还应具有外部有效性,以便适用于将应用该测试的其他人群。迄今为止发表的17项非常不同的评估VIA测试准确性的研究体现了所有这些考虑因素。对新筛查测试的评估是研究新癌症预防策略的第一步。因此,应通过严格的研究仔细处理这一步骤。